The Chartered Group made the strategic investment.
The company intends to use the funds for the development of new AI models to further increase molecular discovery efficacy while reducing risk for the next stages of development.
Led by Immanuel Lerner, Founder and CEO, Pepticom leverages artificial intelligence (AI) technology that streamlines and accelerates the ability of researchers to discover advanced peptide-based drug candidates. Peptides are used in various therapies, and are recognized for being highly selective and efficacious as well as relatively safe.
Pepticom’s technology covers a chemical-space of 1030 possible molecular options while simultaneously filtering out the most suitable candidates with properties such as solubility and permeability amongst others.
The company was founded in 2011 by a select team of multidisciplinary PhD graduates from The Hebrew University of Jerusalem with technology licensed from Yissum, the technology transfer company of The Hebrew University.
FinSMEs
24/10/2019